Global demand continues to exceed supply, to be addressed by new manufacturing facilities
Porton Biopharma Limited (“PBL”), the UK biopharmaceutical, development and manufacturing company, notes yesterday’s full year financial results announcement from Jazz Pharmaceuticals PLC, which confirmed that Erwinase®, the Company’s life-saving cancer treatment, recorded sales of more than $177 million in 2019, up 2%.
Erwinase is prescribed for acute lymphoblastic leukaemia, a cancer of the blood predominantly affecting children. The majority of sales in 2019 were in the US though the product is sold in more than 80 countries worldwide including the UK, one of its largest markets.
PBL has made significant investment in resources and devoted effort into ensuring that it manufactures the product which saves the lives of thousands of children every year. This has included more than £50 million in new manufacturing facilities to increase production capacity, which are expected to start to become operational in the second half of 2020.
Roger Hinton, PBL’s Managing Director, said: “During 2019 we have successfully manufactured every batch on schedule but unfortunately demand has again exceeded supply. To meet that challenge, we continue to make progress in increasing capacity to supply this lifesaving product worldwide. We have made a very substantial investment in expanding our manufacturing facilities during the past few years and we look forward to this capacity beginning to come on stream from the second half of this year.”